Video summary

Semiopatologia Quirúrgica UBA SDRC

Main summary

Key takeaways

Science and Nature

Scientific concepts, discoveries, and nature/medical phenomena

Condition and nomenclature

  • Complex Regional Pain Syndrome (CRPS): a chronic, painful disorder with varied clinical presentations and a defined set of signs and symptoms (“syndrome”).
  • Historical terms mentioned:
    • Causalgia: term used by an American Civil War surgeon for limb pain after injury with nerve damage.
    • Sudek’s osteoporosis: attributed to a radiological description; the speaker argues it is not always present early (e.g., ~30% may lack radiographic osteoporosis initially), so the term is not adequate.
    • International Association for the Study of Pain terminology: the speaker notes CRPS as the unified term.

Types of CRPS and pain mechanisms

  • CRPS type 1 (historically): previously framed as “reflex sympathetic dystrophy.”
    • Generally linked to nociceptive pain (e.g., after fractures, post-surgery, some carpal tunnel-related settings).
  • CRPS type 2: similar symptom pattern, but due to peripheral nerve lesions (nerve trunk / brachial plexus).
  • A third type added later (CRPS type 3):
    • Defined by pain becoming chronic without the characteristic pattern of reflex sympathetic dystrophy and without nerve lesions.
    • The speaker links this to nociplastic pain.

Harden’s clinical subtypes (Budapest/postulate framework)

Harden is described as modifying/extending diagnostic criteria (Budapest postulates) and dividing presentations into:

  • Limited syndrome with vasomotor predominance
  • Limited syndrome with predominance of neuropathic pain and sensory disturbances
  • Florid syndrome (full constellation of symptoms)

Etiopathogenesis: evolving model

Earlier triad (described as necessary)

  • Trauma (not exclusively): examples mentioned include stroke and “myocardial impact,” alongside typical limb injury.
  • Abnormal sympathetic reflex: the sympathetic system is emphasized for disease genesis and continuity.
  • Emotionally unbalanced / psychologically vulnerable personality:
    • Examples include depression, chronic pain history, fibromyalgia, anxiety, migraines.

More recent proposed factors (last several years)

  • Genetic/hereditary tendency: familial clusters and candidate genes reported, though not universally accepted.
  • Immune/autoimmune signal:
    • Reported increased IgG and IgM
    • Improvement with corticosteroids supports immune involvement
  • Central sensitization:
    • The central nervous system becomes hypersensitized, making pain chronic and broadening symptom expression.

Three pain categories discussed

  • Nociceptive pain: arises from altered nociceptors.
  • Neuropathic pain: arises from nerve damage.
  • Nociplastic pain (speaker’s emphasis; aligned with CRPS type 3):
    • Becomes chronic
    • No consistent history of neuropathic/nociceptive origin
    • Associated with psychosocial alterations
    • Hypersensitivity/allodynia emphasized as diagnostically key

Pain phenotype differentiations (as stated)

  • Nociplastic pain
    • Often described as localized stabbing/throbbing pain (“well-localized”)
    • Often associated with negative scintigraphy and positive response to nerve blocks
    • Speaker cautions that evidence reliability is limited
  • Neuropathic pain
    • Diffuse/disproportionate pain with motor dysfunction and sympathetic alterations
    • Described as burning pain
    • Positive scintigraphy
    • “Positive response” to sympathetic block is described as debated/doubtful
  • Nociplastic pain duration rule:
    • Lasts at least 3 months
    • Includes fatigue, insomnia, depression, cognitive/autonomic dysfunction, and motor/sensory alterations

Sensitization and neuroinflammation pathway

Mechanistic sequence described:

  • Peripheral sensitization: increased response to pain stimulus + decreased pain threshold.
  • Amplification and transmission: spinal cord → brain.
  • Neuropeptide release at the spinal cord level → neuroinflammation.
  • Neuroinflammation → central sensitization → ongoing hypersensitivity and allodynia.

Neuropeptides/substance mediators listed:

  • Substance P
  • Bradykinin
  • Histamine
  • Prostaglandin
  • Serotonin
  • Inflammatory cytokines

Central vs sympathetic roles over time

  • Early on: sympathetic dysfunction (“sympathetic diffusion”) coincides with disease onset.
  • Over time: sympathetic parameters may normalize, but central dysfunction develops/expands and drives chronicity.
  • Proposed autonomic effects include:
    • temperature regulation
    • vital signs
    • immune regulation
    • limbic system function Linked symptoms include insomnia, irritability, depression/anxiety, and panic attacks.

Acute vs chronic pain distinction (clinical framing)

  • Acute pain
    • Symptom-like, proportional to stimulus, transient
    • Associated with anxiety
    • Responds well to treatment
  • Chronic pain
    • Disease-like, not proportional, permanent
    • Associated with depression
    • Response is slower/“fair”
    • Analogy used: “The Scream” for acute pain; another painting to represent chronic depression state.

Clinical manifestations described for CRPS/CRPS-spectrum pain

Core pain features

  • Hyperpathia: exaggerated pain to painful stimuli.
  • Allodynia: pain from non-painful stimuli (e.g., cotton, a drop of water).
  • Inactivity pain: pain when the limb isn’t moved.

Motor/vascular/sensory/autonomic features

  • Edema + stiffness early
    • Neuroinflammation with vasodilation and plasma extravasation
    • Protein deposition around joints/ligaments → thickening of joint capsule → stiffness
    • Synovial tissue deterioration over time
  • Sensory disturbances may occur early, including possible neurocompressive syndromes (e.g., carpal tunnel).
  • Palmar fasciitis pattern resembling muscular dystrophy/dystrophy, affecting 4th and 5th fingers
    • Speaker notes it may persist even if other symptoms improve.
  • Color and temperature changes
    • Often hot hand early
    • Sweating changes; early hyperhidrosis
  • Late/chronic motor changes
    • Flexor muscle spasms, dystonia
    • Tremor: speaker claims >50% in chronic disease
  • Emotional/central dysfunction symptoms
    • insomnia, irritability
    • depression/anxiety/panic attacks

Imaging and brain plasticity findings (MRI)

  • Speaker describes NMR/MRI evidence of altered brain regions:
    • changes in gray matter in hemispheric areas representing the affected limb
    • hypothalamic changes
    • changes in regions linked to pain processing
  • Cortical representation analogy:
    • hands have large cortical representation; motor representation larger than sensory
  • Example described:
    • decreased finger cortical separation distance in the affected hemisphere
    • partial recovery after 1 year of treatment, interpreted as neuroplasticity

Clinical staging

Modern framing described:

  • Hot clinical stage: early—hand hot and numb
  • Cold clinical stage: chronic—hand cold and dry

Three-stage framework attributed to “Monica”:

  • Stage 1: inflammatory (~3 months; ideal for initiating treatment)
  • Stage 2: dystrophic (> inflammatory phase)
    • edema decreases while stiffness increases
    • hand tends colder
  • Stage 3: atrophic (>12 months)
    • total hand atrophy and joint stiffness
    • difficult to treat

Risk factors and epidemiology (as stated)

  • Sex: women more frequently (speaker cites ~4x to 6x).
  • Comorbid pain/psychiatric risk:
    • fibromyalgia, depression, chronic pain history, anxiety-prone state, migraines
  • Injury risk distribution (speaker-given percentages):
    • ~42–45% fractures
    • ~20-something% closed trauma/sprain
    • ~12% postoperative
    • ~7% neurocomplex syndromes (e.g., carpal tunnel)
    • ~7% unclear etiology
  • Treatment-related contributors
    • tight garments/positioning (counterproductive)
    • prolonged immobilization
    • overuse of external fixators (speaker says decreased)
    • mechanoreceptor disturbance proposed with:
      • external fixators with ligamentous arthroscopy
      • arthroscopy with significant joint capsule distension (e.g., knee arthroscopy with large water volumes)

Diagnostic methodology (clinical + imaging)

  • Diagnosis is primarily clinical, using Budapest postulates (simplified latest version referenced, not reproduced verbatim).
  • Scintigraphy (bone scan):
    • used for doubtful cases
    • used in medico-legal contexts to “certify” diagnosis
  • Radiology considerations:
    • early imaging may show no alterations
    • speaker reports ~30% may lack radiological osteoporosis early
  • Bone scintigraphy rules described:
    • “three-phase bone scan”; all three phases must be positive (as claimed by speaker)
    • positive in initial stages, negative in terminal stages
    • in children: “pseudodystrophy” rather than CRPS (speaker states scintigraphy negative)
  • Diagnostic accuracy (as stated):
    • sensitivity 96%, specificity 98% (attributed to Harden and related work)

Treatment concepts and methodology (outlined)

Three-pillar approach (must begin early and simultaneously)

  • Specific medication
  • Physiotherapy / physical therapy
  • Psychotherapeutic support

Key principles emphasized:

  • Start as early as possible (especially within the early inflammatory window).
  • Avoid delays from “wait and see” before tri-therapy is organized.
  • Patient education is treated as essential:
    • explain diagnosis
    • expected course
    • that improvement is possible with correct treatment

Medication approach described

  • Calcitonin (nasal) historically used with “very good results,” but unavailable in Argentina; replaced by:
    • Corticosteroids initially (not too high doses)
    • Pregabalin (for neuropathic/CNS pain), titrated from low dose upward
    • Antidepressants added frequently due to depression comorbidity
    • Analgesics/opioids handled carefully due to centrally mediated neurologic pain and dependence risk.

Physiotherapy principles (as stated; “Marcela” to cover details)

  • Avoid passive mobilizations that cause pain.
  • Avoid ice (speaker claims counterproductive).
  • Avoid immobilization; remove wrist immobilizers when appropriate and mobilize early.

Anesthesia-related preventive/management note

  • Use long-acting nerve blocks (including brachial plexus blocks) so postoperative awakening is less painful and reduces fear-driven worsening risk.

Vitamin C note

  • Mention of a prior “fashionable” Lancet study; speaker cites newer evidence that it may not work as intended.

Advanced-stage management options

  • Referral to a pain management team if standard management fails.
  • Trigger point surgery in selected scenarios.
  • Arthrolysis and capsulectomy for severe metacarpal stiffness in selected patients.

Prevention strategies summarized

  • Manage patient risk factors (e.g., depression, fibromyalgia).
  • Reduce immobilization time; mobilize fractures/injuries earlier (even tendon surgery mobilized day 3–4).
  • Avoid compressive bandages.
  • Provide postoperative analgesia via nerve blocks to prevent severe awakening pain.

Functional outcome statement

  • Even with best efforts, the speaker states 25–35% may remain with some degree of disability (residual impairment).

Researchers or sources featured (named)

  • Hugo Fernando Caloa (presenting; hand surgeon)
  • Suec (attributed to “Sudek’s osteoporosis,” described as 1900)
  • Harden (Budapest postulates modification; diagnostic accuracy claims)
  • International Association for the Study of Pain (term “CRPS” / nomenclature unification)
  • Monica (used for the clinical staging framework: inflammatory/dystrophic/atrophic)
  • Edgard Mun (referenced for the painting “The Scream”)
  • Bang (referenced for chronic pain painting)
  • Marcela (named colleague involved in treatment/physiotherapy discussion; surname not given)
  • Lancet Institute / Lancet-related vitamin C study (authors not specified)
  • Valencia meeting (conference location referenced for pain-type addition; organizers/authors not specified)

Original video